The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Targeted Prostate Cancer Screening in BRCA1 and BRCA2 Mutation Carriers: Results from the Initial Screening Round of the IMPACT Study.

På svenska

Author

  • Elizabeth K Bancroft
  • Elizabeth C Page
  • Elena Castro
  • Hans Lilja
  • Andrew Vickers
  • Daniel Sjoberg
  • Melissa Assel
  • Christopher S Foster
  • Gillian Mitchell
  • Kate Drew
  • Lovise Mæhle
  • Karol Axcrona
  • D Gareth Evans
  • Barbara Bulman
  • Diana Eccles
  • Donna McBride
  • Christi van Asperen
  • Hans Vasen
  • Lambertus A Kiemeney
  • Janneke Ringelberg
  • Cezary Cybulski
  • Dominika Wokolorczyk
  • Christina Selkirk
  • Peter J Hulick
  • Anders Bojesen
  • Anne-Bine Skytte
  • Jimmy Lam
  • Louise Taylor
  • Rogier Oldenburg
  • Ruben Cremers
  • Gerald Verhaegh
  • Wendy A van Zelst-Stams
  • Jan C Oosterwijk
  • Ignacio Blanco
  • Monica Salinas
  • Jackie Cook
  • Derek J Rosario
  • Saundra Buys
  • Tom Conner
  • Margreet G Ausems
  • Kai-Ren Ong
  • Jonathan Hoffman
  • Susan Domchek
  • Jacquelyn Powers
  • Manuel R Teixeira
  • Sofia Maia
  • William D Foulkes
  • Nassim Taherian
  • Marielle Ruijs
  • Apollonia T Helderman-van den Enden
  • Louise Izatt
  • Rosemarie Davidson
  • Muriel A Adank
  • Lisa Walker
  • Rita Schmutzler
  • Kathy Tucker
  • Judy Kirk
  • Shirley Hodgson
  • Marion Harris
  • Fiona Douglas
  • Geoffrey J Lindeman
  • Janez Zgajnar
  • Marc Tischkowitz
  • Virginia E Clowes
  • Rachel Susman
  • Teresa Ramón Y Cajal
  • Nicholas Patcher
  • Neus Gadea
  • Allan Spigelman
  • Theo van Os
  • Annelie Liljegren
  • Lucy Side
  • Carole Brewer
  • Angela F Brady
  • Alan Donaldson
  • Vigdis Stefansdottir
  • Eitan Friedman
  • Rakefet Chen-Shtoyerman
  • David J Amor
  • Lucia Copakova
  • Julian Barwell
  • Veda N Giri
  • Vedang Murthy
  • Nicola Nicolai
  • Soo-Hwang Teo
  • Lynn Greenhalgh
  • Sara Strom
  • Alex Henderson
  • John McGrath
  • David Gallagher
  • Neil Aaronson
  • Audrey Ardern-Jones
  • Chris Bangma
  • David Dearnaley
  • Philandra Costello
  • Jorunn Eyfjord
  • Jeanette Rothwell
  • Alison Falconer
  • Henrik Gronberg
  • Freddie C Hamdy
  • Oskar Johannsson
  • Vincent Khoo
  • Zsofia Kote-Jarai
  • Jan Lubinski
  • Ulrika Axcrona
  • Jane Melia
  • Joanne McKinley
  • Anita V Mitra
  • Clare Moynihan
  • Gad Rennert
  • Mohnish Suri
  • Penny Wilson
  • Emma Killick
  • Sue Moss
  • Rosalind A Eeles
Show all

Summary, in English

Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls) is an international consortium of 62 centres in 20 countries evaluating the use of targeted PCa screening in men with BRCA1/2 mutations.

Publishing year

2014-01-15

Language

English

Publication/Series

European Urology

Document type

Journal article

Publisher

Elsevier

Topic

  • Urology and Nephrology

Status

Published

Research group

  • Clinical Chemistry, Malmö

ISBN/ISSN/Other

  • ISSN: 1873-7560